Start the conversation
Shares of Dutch pharmaceutical firm Prosena Holding NV (Nasdaq: RNA) jumped nearly 70% in premarket hours on news that it will be acquired for $680 million. According to reports, BioMarin Pharmaceuticals Inc. (Nasdaq: BMRN) has offered $17.75 per share. The deal could be worth significantly more however, if certain Prosensa drugs receive regulatory approval. Meanwhile, RenaissanceRe Holdings Ltd. (NYSE: RNR) has agreed to purchase Platinum Underwriters Holdings Ltd (NYSE: PTP) for $1.9 billion.